Peptide Half-Life Calculator Guide: How It Works, What It Tells You & Worked Examples

Peptide half-life calculator guide: what half-life means for dosing frequency, how to use the calculator, and worked examples for BPC-157, CJC-1295, and semaglutide.

→ Open the Peptide Half-Life Calculator

Enter your peptide's half-life, last dose, and dose amount to see how much remains in your system at any time point.

TL;DR — Peptide Half-Life at a Glance

• Half-life is the time required for the active concentration of a peptide to decrease by 50% — it determines how often a compound must be dosed to maintain research-relevant concentrations
• Short half-life peptides (GHRPs, BPC-157) require multiple daily doses; long half-life peptides (CJC-1295 DAC, Semaglutide) can be dosed once weekly or less
• General rule: stable blood levels require dosing at an interval of approximately 1.5–2x the half-life
• Dosing timing relative to cortisol rhythms and GH pulsatility significantly affects the GH axis peptide data you collect
• Use the peptide half-life calculator to plan your dosing schedule →

⚠️ Research Disclaimer: All peptides referenced in this guide are research compounds not approved by the FDA for human use. All information is for educational purposes only and does not constitute medical advice.

The peptide half-life calculator is one of the most practically useful tools for structuring research dosing protocols, yet half-life is also one of the most commonly misunderstood pharmacokinetic parameters among researchers new to peptide work. Understanding half-life goes far beyond simply knowing "how long the peptide lasts" — it determines dosing frequency, affects the interpretation of blood concentration data, governs whether a compound will accumulate to steady state over a multi-day protocol, and shapes when in relation to physiological rhythms an injection should ideally be placed.

This guide explains what peptide half-life means in practical terms, reviews the half-lives of major research peptides across the spectrum from very short (minutes) to very long (days), provides the pharmacokinetic logic for converting half-life data into optimal dosing intervals, and demonstrates how to use the half-life calculator to design more precise research protocols. Half-life data interacts directly with reconstitution and dosing math — both of which are covered in the companion peptide dosage calculator guide.

What Peptide Half-Life Means: The Pharmacokinetics Explained

Half-life (t½/₂) is the time required for the plasma concentration of an active compound to fall to 50% of its peak value following administration. For peptides administered subcutaneously, peak plasma concentration typically occurs 15–45 minutes post-injection (longer for high-molecular-weight or depot formulations), and then declines following first-order kinetics — meaning the rate of elimination is proportional to the current concentration. This produces the characteristic exponential decay curve seen in pharmacokinetic studies.

After one half-life, 50% of the compound remains. After two half-lives, 25% remains. After three, 12.5%. After five half-lives, less than 4% of the original dose remains — this is the practical threshold at which most pharmacologists consider a compound effectively cleared. This five-half-life clearance rule is important for research protocol design: when calculating wash-out periods between experimental conditions, allowing five half-lives to elapse ensures minimal carry-over from the previous dose.

Conversely, when a compound is dosed repeatedly at fixed intervals, it accumulates toward a steady-state concentration. Steady state is reached after approximately four to five half-lives of repeated dosing. For short-acting peptides like Ipamorelin (half-life ~2 hours), steady state on a twice-daily protocol is reached within the first day. For long-acting peptides like CJC-1295 with DAC (half-life ~8 days), steady state on a twice-weekly protocol takes approximately 3–4 weeks to establish. This steady-state timeline affects how soon after protocol initiation experimental measurements reflect the intended steady-state exposure.

Peptide Half-Life Reference Table: From Short-Acting GHRPs to Long-Acting Analogs

The following table provides half-life data for major research peptides across all major categories. All values are approximate and can vary with injection site, subject characteristics, and reconstitution conditions.

How Half-Life Determines Peptide Dosing Frequency: The 1.5x Rule

A useful practical rule for converting half-life to dosing interval is: dose at an interval of approximately 1.5 to 2 times the half-life to maintain plasma concentrations within a therapeutically relevant range between doses. This rule emerges from the pharmacokinetics of first-order elimination: dosing at exactly one half-life interval means concentrations never fall below 50% of peak before the next dose, which for most research compounds is an acceptable trough concentration.

For peptides where you specifically want pulsatile rather than sustained exposure — notably the GHRPs and GHRH analogs used in GH axis research — the timing logic is different. GH secretion is naturally pulsatile, and mimicking pulsatility requires ensuring concentrations fall close to baseline between doses. For these compounds, spacing injections 4–8 hours apart (well beyond their ~30-minute half-life) allows each dose to produce a distinct, identifiable GH pulse that more closely mirrors physiological GH secretion patterns.

For BPC-157, which has a half-life of approximately 4 hours, a twice-daily injection schedule (roughly 8–12 hours between doses) leaves a meaningful trough period but maintains reasonable daily exposure. Whether continuous vs pulsatile exposure is more relevant depends on the specific research question — tissue repair research may benefit from more sustained exposure, while studies examining acute GH pulsatility specifically require distinct peaks with full inter-dose clearance.

Practical Dosing Schedule Examples: BPC-157, CJC-1295, and Semaglutide

BPC-157 (half-life ~4 hours): A once-daily 500 mcg injection produces a peak followed by near-full clearance within 20 hours (5 half-lives). A twice-daily schedule (250 mcg per dose, 8–12 hours apart) maintains meaningful circulating concentrations for a greater fraction of the day. Research designs examining cumulative tissue repair outcomes typically use twice-daily protocols for this reason. Explore more in the BPC-157 complete research guide.

CJC-1295 with DAC (half-life ~8 days): This is the longest-acting GHRH analog in common research use. Its Drug Affinity Complex (DAC) technology allows CJC-1295 to bind serum albumin after injection, creating a slow-release depot that extends the half-life from the ~30-minute window of non-DAC CJC-1295 to approximately 8 days. A once-weekly injection produces relatively stable circulating levels across the week, with trough concentrations that are still functionally active (typically >50% of peak). Twice-weekly dosing provides even more stable levels but may not be necessary for most research designs. Steady state on once-weekly dosing is established approximately 4–5 weeks into the protocol.

Semaglutide (half-life ~7 days): Once-weekly subcutaneous dosing produces very stable pharmacokinetic profiles with trough-to-peak ratios within the same order of magnitude. Steady state is reached after 4–5 weeks on a fixed weekly dose. The long half-life is pharmacologically advantageous for maintaining GLP-1 receptor activation between doses but also means dose adjustments take weeks to stabilize at a new steady state — an important consideration for research designs that modify dose mid-protocol. The CJC-1295 and Ipamorelin stack guide discusses how long-acting and short-acting compounds interact within the same stack.

Why GH Peptides Are Timed Around Cortisol Rhythms and Sleep

For GH axis research specifically, the timing of peptide injection relative to physiological rhythms meaningfully affects the GH response magnitude and the quality of research data. Growth hormone is secreted in discrete pulses, with the largest pulse occurring in the first 90 minutes of deep slow-wave sleep. Cortisol, which opposes GH action at multiple levels, follows a diurnal rhythm with peak levels in the early morning and troughs in the late afternoon and evening.

Three timing considerations emerge from this physiology:

1. Pre-sleep injection of a GHRP + GHRH combination amplifies the natural nighttime GH pulse — this is the protocol most research designs use when studying maximum GH pulse amplitude. The cortisol trough at sleep onset reduces somatostatin tone and allows GHRPs to drive a larger GH response.

2. Fasted injection (≥3 hours post-meal) is recommended because elevated insulin levels from recent food intake increase somatostatin secretion and blunt the GH response to GHRP administration. Fasted state correlates with lower insulin, lower somatostatin, and larger GH pulses.

3. Morning injection timing studies show reduced GH responses due to elevated cortisol — this timing is used when researchers specifically want to study GH responses under physiological stress-hormone conditions.

For long-acting peptides like CJC-1295 DAC and Semaglutide, circadian timing has less impact because the compound is present continuously; the pulsatile GH dynamic is only relevant for short-acting compounds where the timing of the injection defines the timing of the pharmacological peak.

Stack Timing Considerations When Multiple Compounds Have Different Half-Lives

When building a peptide stack with compounds of different half-lives, injection scheduling becomes a multi-dimensional challenge. The how to build a peptide research stack guide covers stack design broadly, but half-life timing is worth addressing specifically here.

Consider a common CJC-1295 (no DAC) + Ipamorelin twice-daily protocol: both compounds have short half-lives and are typically co-injected at the same time points (morning and evening/pre-sleep). Because they act synergistically, simultaneous administration maximizes the combined GH pulse. In this case, matching injection times is both practical and pharmacologically optimal.

For a BPC-157 + TB-500 recovery stack, the timing logic differs: TB-500 has a multi-day half-life and is dosed weekly, while BPC-157 is dosed daily or twice daily. There is no requirement to co-inject them at the same time, and their complementary mechanisms operate through different pathways, so temporal overlap of peak concentrations is less critical than for synergistic GH secretagogues.

How to Use the Peptide Half-Life Calculator

The peptide half-life calculator accepts compound name (from the database) or manual half-life entry, your target dosing frequency, and dose amount. It outputs:

• The expected plasma concentration curve over 24–72 hours based on your dosing schedule
• Trough concentration as a percentage of peak (helpful for assessing whether inter-dose troughs remain pharmacologically relevant)
• Days to steady state on your current dosing frequency
• Recommended adjustment if your inter-dose interval does not match the pharmacokinetic profile of the compound

For researchers combining two compounds with different half-lives, the calculator can model both simultaneously and display overlapping concentration curves, making timing interactions visible at a glance. This is particularly useful for stacks that include both a short-acting and long-acting version of a compound class (such as CJC-1295 with DAC plus an acute GHRP).

Frequently Asked Questions About Peptide Half-Life

Q: What is peptide half-life and why does it matter for dosing? A: Half-life (t½/₂) is the time for a peptide's plasma concentration to fall by 50% after peak. It matters because it directly determines how often a compound must be injected to maintain research-relevant concentrations. A peptide with a 30-minute half-life clears from the system in about 2.5 hours (five half-lives) — it must be dosed multiple times daily to maintain any sustained exposure. A peptide with an 8-day half-life maintains meaningful concentrations for weeks from a single injection.

Q: How does half-life affect how often you should inject peptides? A: As a working rule, dosing at intervals of 1.5–2x the half-life prevents concentrations from falling below roughly 50% of peak between doses, maintaining a relatively consistent research exposure. For pulsatile GH research, spacing injections well beyond the half-life (4–6+ hours for ~30-minute GHRPs) allows for distinct, identifiable GH pulses that better reflect physiological secretion patterns. The optimal interval depends on the research question: sustained exposure vs pulsatile peaks have different optimal dosing intervals.

Q: Where can I find a peptide half-life calculator for research planning? A: The peptide half-life calculator on this site allows you to model plasma concentration curves for any peptide based on half-life and dosing schedule. You can select from compounds already in the database or enter a custom half-life value. The calculator outputs trough-to-peak ratios, steady-state timing, and graphical concentration curves that you can use to adjust injection scheduling before initiating a research protocol.

Q: Why is CJC-1295 with DAC dosed once weekly instead of daily? A: CJC-1295's Drug Affinity Complex (DAC) technology allows the peptide to bind serum albumin after injection, using albumin as a natural slow-release depot. This extends the biological half-life from approximately 30 minutes (CJC-1295 without DAC) to approximately 8 days. With an 8-day half-life, once-weekly dosing maintains trough concentrations that are still 50–60% of peak by the next injection, providing relatively stable circulating levels. Daily dosing would produce unnecessary accumulation and is not pharmacokinetically justified for the DAC formulation.

Q: Does the method of reconstitution or storage affect peptide half-life? A: Reconstitution method does not alter the pharmacokinetic half-life of a peptide once administered, as half-life reflects metabolic clearance processes in the body rather than preparation characteristics. However, improper storage or reconstitution can degrade the peptide before administration, effectively reducing the active fraction of the dose — which can look like altered pharmacokinetics in research data but is actually a dosing accuracy issue. Using appropriate reconstitution solvents (BAC water for most peptides, acetic acid for IGF-1 variants) and proper refrigerated storage protects compound integrity and ensures the intended dose is what is actually delivered.

All content is for educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions